Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563411 | 0.90 | AR (0.54) | LMNASMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL3552602 | 0.90 | LMNA (0.62) | LMNASMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL3555874 | 0.90 | CA12 (0.56) | LMNASMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL3560475 | 0.90 | HDAC1 (0.55) | LMNASMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL3562939 | 0.90 | AR (0.58) | LMNASMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL3558099 | 0.89 | FABP1 (0.54) | LMNASMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL3552400 | 0.89 | AR (0.60) | LMNASMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL3553720 | 0.88 | MEN1 (0.53) | LMNASMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL3553481 | 0.88 | AR (0.58) | LMNASMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL3556914 | 0.88 | WDR5 (0.52) | LMNASMN1; SMN2MEN1KMT2AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| EP-1761486-A1 | PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2007-03-14 | — | — | EP | claimed |
| WO-2006000288-A1 | PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2006-01-05 | — | — | WO | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | LMNA 2120/4885SMN1; SMN2 4522/4885MEN1 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.